Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. SAKK

Weber, W.; Laffer, U.; Metzger, U.

Anticancer Research 13(5C): 1839-1840

1993


ISSN/ISBN: 0250-7005
PMID: 8267390
Document Number: 407962
Between 1981 and 1987, 533 patients from 9 institutions were entered in a randomized trial to assess the value of adjuvant perioperative portal infusion with Fluorouracil and Mitomycin as compared to radical surgery alone. Analysis of 469 evaluable patients at a median follow-up of 5.8 years revealed 110 recurrences in the control and 94 recurrences in the infusion group. Estimated 5-year disease-free survival was 52% and 61% respectively (hazard ratio: 1:0. 75; 95% confidence interval 0.57-0.99, p = 0.046). Overall survival was 59% in the control and 69% in the infusion group (p = 0. 048). Adjuvant portal infusion did not influence the occurrence of liver metastases but reduced the overall recurrence rate.

Document emailed within 1 workday
Secure & encrypted payments